Held by 3 specialist biotech funds
High Convergence**Signal Note: OrbiMed Entry into FOLD** OrbiMed's $10.4M initiation suggests conviction in Amicus's pipeline, likely driven by upcoming catalysts around migalastat (Galafold) label expansions or Phase 2/3 readouts in fabry disease variants and potentially other lysosomal storage disorders.
AI analyst context — unlock full analysis
**Signal Note: Rock Springs Capital Initiates $27.5M FOLD Position** Rock Springs' new position likely reflects conviction in Amicus's commercial execution of migalastat for Fabry disease, a rare lysosomal storage disorder with limited competitive options and strong pricing power (~$250K+ annually). The timing suggests confidence in upcoming efficacy readouts or reimbursement expansion, though near-term catalysts (pipeline data, label expansions) should be monitored given the concentrated position size relative to typical biotech holdings.
+ 1more — see how much conviction went in
See the Full Story